

ICA FOUNDATION

International Contraceptive Access




ICA FOUNDATION

- Public-private partnership between Population Council and Bayer Healthcare Pharmaceuticals
- Not-for-profit registered in Finland in 2004
- Provides contraceptive products, e.g., levonorgestrel releasing intrauterine system (LNG IUS) to public health organizations such as multilaterals, governments, or NGOs for use in their programs
- Aims to serve the reproductive needs of women and families in resource-poor settings in developing countries
- Member of the Reproductive Health Supplies Coalition

LEVONORGESTREL INTRA-UTERINE SYSTEM

- The LNG IUS contraceptive was developed in the 1970s by Population Council and Bayer Oy, combining the best features of both oral contraceptives and the IUD.
- Product consists of a T-shaped plastic frame and white cylinder shaped hormone reservoir around the vertical arm of the frame, with two nylon threads for removal.
- The system contains 52 mg of the hormone levonorgestrel (LNG) and releases $20\mu\text{g}/24\text{h}$ in the uterus for up to five years of protection.
- Registered in 3 countries (Ghana, Kenya and Nigeria)
- Mirena has been commercially available since 1990, currently registered in over 120 countries



CHARACTERISTICS OF LNG IUS



- Highly effective: failure rate ~0.2% at 1 year and cumulative failure rate 0.7% at 5 years
- High continuation rate: more than 90% of users continue each year of use
- Significantly reduces menstrual blood loss
- Approved treatment for women suffering of heavy menstrual bleeding
- Rapid return to fertility after removal
- More cost-effective than oral contraceptives, condoms and injectable contraception over five years

Sources: Bayer AG: LNG IUS Corporate Core Data Sheet Jan 2014
Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335–9
Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel releasing intrauterine device and Nova T. Contraception 1992;45:575–84
Trussell J. Update on the cost-effectiveness of contraceptives in the United States. Contraception 2010;82:391

ICA FOUNDATION INVENTORY

- The ICA Foundation offers donations of LNG IUS to public sector
- Donations of LNG IUS make up to 1% of non-US market sales of Mirena® annually

LNG IUS DONATION PROCEDURES

- Service delivery organization submit LNG IUS project proposal to ICA Foundation
- LNG IUS is registered or special permission to import and use the product is sought from country of donation
- Training materials are provided regarding LNG IUS insertion/removal and comprehensive family planning provision and counseling
- LNG IUS is incorporated into existing service delivery strategy
- Donation recipient provides updates on numbers of insertions as well as progress and possible challenges of distribution



Who can apply for LNG IUS?

International development and public health organizations, such as multilateral, governmental, or non-governmental organizations for use in their programs. LNG IUS donations are not available for biomedical research purposes, including clinical trials.

How to apply?

Interested applicants should complete a project proposal form on ICA Foundation's website and submit it for assessment and approval.


For more information please contact ICA Foundation:

Mailing address: ICA Foundation, PO Box 581, FI-20101 Turku, Finland

E-mail: information@ica-foundation.org

Website: <http://www.ica-foundation.org>

ICA CUMULATIVE DONATIONS: 69,940 LNG IUS (May 2015)



COUNTRY PROJECTS



Latin America

- Bolivia
- Brazil
- Colombia
- Curacao
- Dominican Rep.
- Ecuador
- El Salvador
- Haiti
- Mexico
- Paraguay
- Saint Lucia

Africa

- DR Congo
- Ethiopia
- Ghana
- Kenya
- Lesotho
- Malawi
- Nigeria
- South Africa
- Uganda
- Zambia
- Zimbabwe

Asia

- Afghanistan
- Bangladesh
- Cambodia
- Indonesia
- Mongolia
- Sri Lanka